Sharma P, Goswami S, Raychaudhuri D, Siddiqui BA, Singh P, Nagarajan A, et al. Immune checkpoint therapy-current perspectives and future directions. Cell. 2023;186(8):1652–69.

Article  CAS  PubMed  Google Scholar 

Kooshkaki O, Derakhshani A, Hosseinkhani N, Torabi M, Safaei S, Brunetti O, et al. Combination of Ipilimumab and Nivolumab in cancers: from clinical practice to ongoing clinical trials. Int J Mol Sci. 2020. https://doi.org/10.3390/ijms21124427.

Article  PubMed  PubMed Central  Google Scholar 

Wolchok JD, Chiarion-Sileni V, Rutkowski P, Cowey CL, Schadendorf D, Wagstaff J, et al. Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2025;392(1):11–22.

Article  CAS  PubMed  Google Scholar 

Huang L, Guo Y, Liu S, Wang H, Zhu J, Ou L, et al. Targeting regulatory T cells for immunotherapy in melanoma. Mol Biomed. 2021;2(1):11.

Article  PubMed  PubMed Central  Google Scholar 

Jiang X, Rudqvist NP, Jiang B, Ye S, He S, Liang Q, et al. Depletion of effector regulatory T cells associates with major response to induction dual immune checkpoint blockade. Cancer Discov. 2025;15(8):1569–92.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lax BM, Palmeri JR, Lutz EA, Sheen A, Stinson JA, Duhamel L, et al. Both intratumoral regulatory T cell depletion and CTLA-4 antagonism are required for maximum efficacy of anti-CTLA-4 antibodies. Proc Natl Acad Sci U S A. 2023;120(31):e2300895120.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tay C, Tanaka A, Sakaguchi S. Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy. Cancer Cell. 2023;41(3):450–65.

Article  CAS  PubMed  Google Scholar 

Dingman R, Balu-Iyer SV. Immunogenicity of protein pharmaceuticals. J Pharm Sci. 2019;108(5):1637–54.

Article  CAS  PubMed  Google Scholar 

Swanson SJ. What are clinically significant anti-drug antibodies and why is it important to identify them. Front Immunol. 2024;15:1401178.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhao Y, Li L, Ma J, Roy A, Bello A, Sheng J, et al. Model-informed immunogenicity assessment of Nivolumab as monotherapy and in combination with Ipilimumab. AAPS J. 2025;27(4):79.

Article  CAS  PubMed  Google Scholar 

Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev. 2010;236:219–42.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Carter PJ, Quarmby V. Immunogenicity risk assessment and mitigation for engineered antibody and protein therapeutics. Nat Rev Drug Discov. 2024;23(12):898–913.

Article  CAS  PubMed  Google Scholar 

Sage PT, Paterson AM, Lovitch SB, Sharpe AH. The coinhibitory receptor CTLA-4 controls B cell responses by modulating T follicular helper, T follicular regulatory, and T regulatory cells. Immunity. 2014;41(6):1026–39.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gutierrez AH, Terry FE, Rosenberg AS, Martin WD, De Groot AS. Regulatory T cell epitope content in human antibodies decreases during maturation. Front Immunol. 2025;16:1535826.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lee H, Kingsford C. Kourami: graph-guided assembly for novel human leukocyte antigen allele discovery. Genome Biol. 2018;19(1):16.

Article  PubMed  PubMed Central  Google Scholar 

Concato J, Peduzzi P, Holford TR, Feinstein AR. Importance of events per independent variable in proportional hazards analysis. I. Background, goals, and general strategy. J Clin Epidemiol. 1995;48(12):1495–501.

Article  CAS  PubMed  Google Scholar 

Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol. 1996;49(12):1373–9.

Article  CAS  PubMed  Google Scholar 

Mattei AE, Gutierrez AH, Seshadri S, Tivin J, Ardito M, Rosenberg AS, et al. In silico methods for immunogenicity risk assessment and human homology screening for therapeutic antibodies. MAbs. 2024;16(1):2333729.

Article  PubMed  PubMed Central  Google Scholar 

Opdivo® (nivolumab) [package insert]. Bristol Myers Squibb, Princeton, NJ. 2025. https://packageinserts.bms.com/medguide/medguide_opdivo.pdf. Accessed Aug 2025.

Marcu A, Bichmann L, Kuchenbecker L, Kowalewski DJ, Freudenmann LK, Backert L, et al. HLA ligand atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy. J Immunother Cancer. 2021. https://doi.org/10.1136/jitc-2020-002071.

Article  PubMed  PubMed Central  Google Scholar 

Moise L, Gutierrez AH, Bailey-Kellogg C, Terry F, Leng Q, Abdel Hady KM, et al. The two-faced T cell epitope: examining the host-microbe interface with JanusMatrix. Hum Vaccin Immunother. 2013;9(7):1577–86.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Immune Epitope Database (IEDB). IEDB TIED platform. https://www.iedb.org/. Accessed Aug 2025.

Greenbaum J, Sidney J, Chung J, Brander C, Peters B, Sette A. Functional classification of class II human leukocyte antigen (HLA) molecules reveals seven different supertypes and a surprising degree of repertoire sharing across supertypes. Immunogenetics. 2011;63(6):325–35.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Howard EL, Goens MM, Susta L, Patel A, Wootton SK. Anti-drug antibody response to therapeutic antibodies and potential mitigation strategies. Biomedicines. 2025. https://doi.org/10.3390/biomedicines13020299.

Article  PubMed  PubMed Central  Google Scholar 

Gfeller D, Guillaume P, Michaux J, Pak HS, Daniel RT, Racle J, et al. The length distribution and multiple specificity of naturally presented HLA-I ligands. J Immunol. 2018;201(12):3705–16.

Article  CAS  PubMed  Google Scholar 

Ritz D, Sani E, Debiec H, Ronco P, Neri D, Fugmann T. Membranal and blood-soluble HLA class II peptidome analyses using data-dependent and independent acquisition. Proteomics. 2018;18(12):e1700246.

Article  PubMed  PubMed Central  Google Scholar 

Schuster H, Peper JK, Bosmuller HC, Rohle K, Backert L, Bilich T, et al. The immunopeptidomic landscape of ovarian carcinomas. Proc Natl Acad Sci U S A. 2017;114(46):E9942–51.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sorde L, Spindeldreher S, Palmer E, Karle A. Tregitopes and impaired antigen presentation: drivers of the immunomodulatory effects of IVIg? Immun Inflamm Dis. 2017;5(4):400–15.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 2018;8(9):1069–86.

Article  PubMed  Google Scholar 

Hong MMY, Maleki Vareki S. Addressing the elephant in the immunotherapy room: effector T-cell priming versus depletion of regulatory T-cells by anti-CTLA-4 therapy. Cancers (Basel). 2022. https://doi.org/10.3390/cancers14061580.

Article  PubMed  PubMed Central  Google Scholar 

Matsuura H, Ishino T, Ninomiya T, Ninomiya K, Tachibana K, Honobe-Tabuchi A, et al. High Antigenicity for T(reg) Cells Confers Resistance to PD-1 Blockade Therapy via High PD-1 Expression in T(reg) Cells. Cancer Sci. 2025;116(5):1214–26.